Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS PRESENTED PRECLINICAL FINDINGS ON NOVEL CDK4/2 INHIBITOR AND SMARCA2 PROTAC DEGRADER AT THE 37TH AACR-NCI-EORTC CONFERENCE

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced presentation of the latest preclinical findings from two of its pipeline programs – **the CDK4/2 inhibitor ABK-CDK-1 and the SMARCA2 PROTAC degrader ABK-SM2-1** – at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ("**AACR-NCI-EORTC Conference**"). Both drug candidates demonstrated superior preclinical profiles.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABK-CDK-1 and ABK-SM2-1 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, October 27, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics Presented Preclinical Findings on Novel CDK4/2 Inhibitor and SMARCA2 PROTAC Degrader at the 37th AACR-NCI-EORTC Conference

On 27 October 2025, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced presentation of the latest preclinical findings from two of its pipeline programs – **the CDK4/2 inhibitor ABK-CDK-1 and the SMARCA2 PROTAC degrader ABK-SM2-1** – at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ("**AACR-NCI-EORTC Conference**"). Both drug candidates demonstrated superior preclinical profiles.

Abbisko Therapeutics presented the following findings at the conference:

- **CDK4/2 Inhibitor ABK-CDK-1**

Title: Discovery of ABK-CDK-1, a selective and brain penetrant CDK4/2 inhibitor to overcome resistance of CDK4/6 inhibitors in breast cancer

Session: Poster Session A

Abstract #: A092

Date and Time: Thursday, October 23 2025, 12:30pm-4:00pm (ET)

Background: Cyclin-dependent kinase ("**CDK**") 4/6 inhibitors have demonstrated clinical efficacy in advanced breast cancer and their application has also been expanded into early-stage disease with large patient population. However, the clinical benefit of first-generation CDK4/6 inhibitors – such as palbociclib, ribociclib, and abemaciclib – is limited by CDK6-mediated toxicity and the emergence of resistance driven in part by cyclin E/CDK2 activation. A selective CDK4/2 inhibitor that spares CDK6 and penetrates the blood-brain barrier could provide a differentiated therapeutic option, especially for patients with brain metastases or resistance to existing CDK4/6 inhibitors. Through advanced computational structural analysis and medicinal chemistry effort, we have developed ABK-CDK-1, a novel, selective and brain-penetrant CDK4/2 inhibitor. Preclinical studies demonstrate its good selectivity over CDK6, strong potency in palbociclib-resistant models, robust anti-tumor efficacy, and favorable drug-like properties.

Conclusion: ABK-CDK-1, developed by Abbisko Therapeutics, is a novel selective and brain-penetrant CDK4/2 inhibitor with the potential to address limitations of current CDK4/6 inhibitors. Its promising efficacy, selectivity, and other properties support further preclinical advancement toward clinical development.

- **SMARCA2 PROTAC Degrader ABK-SM2-1**

Title: Discovery and characterization of a highly potent and orally available SMARCA2 PROTAC degrader

Session Type: Spotlight on Proffered Paper (Oral Presentation)

Presenter: Haiyan Ying

Abstract #: LB-C003

Date and Time: Saturday, October 25 2025, 11:45am-12:15pm (ET)

Background: SMARCA2 and SMARCA4 are two mutually exclusive catalytic core subunits of mSWI/SNF ("**BAF**") complexes regulating gene expression through the remodeling of chromatin structure. SMARCA4 is highly mutated in various cancer types, including approximately 10% of non-small cell lung cancers. SMARCA4 demonstrated a strong synthetic lethal relationship with its paralog, SMARCA2. Therefore, therapeutic strategy of selectively degrading SMARCA2 may provide an effective treatment option for patients with SMARCA4 mutated tumors. This study describes the discovery and preclinical characterization of ABK-SM2-1, a novel, potent, selective and orally bioavailable SMARCA2 PROTAC degrader.

Conclusion: The superior preclinical profile of ABK-SM2-1 supports its advancement into preclinical development.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.